267 related articles for article (PubMed ID: 37457564)
21. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Reich K; Leonardi C; Lebwohl M; Kerdel F; Okubo Y; Romiti R; Goldblum O; Dennehy EB; Kerr L; Sofen H
J Dermatolog Treat; 2017 Jun; 28(4):282-287. PubMed ID: 27759463
[TBL] [Abstract][Full Text] [Related]
22. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
23. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.
Hebert AA; Bobonich MA; Rodriguez Capriles C; Gallo G; Li L; Somani N; Ridenour T; Wang Y; Edson-Heredia E; Becker EM
Pediatr Dermatol; 2022 Jan; 39(1):55-60. PubMed ID: 34931346
[TBL] [Abstract][Full Text] [Related]
24. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
25. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
26. Interventions for chronic palmoplantar pustulosis.
Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
[TBL] [Abstract][Full Text] [Related]
27. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
30. Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.
Takahashi MD; Chouela EN; Dorantes GL; Roselino AM; Santamaria J; Allevato MA; Cestari T; de Aillaud ME; Stengel FM; Licu D
Arch Drug Inf; 2010 Mar; 3(1):1-8. PubMed ID: 20428227
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Lockshin B; Harrison RW; McLean RR; Crabtree MM; Konicek BW; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Burge RT
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2797-2815. PubMed ID: 36331713
[TBL] [Abstract][Full Text] [Related]
32. Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
Papp KA; Gerdes S; Leonardi CL; Elmaraghy H; See K; McKean-Matthews M; Konicek BW; Crane HM; Eastman W
J Drugs Dermatol; 2021 Aug; 20(8):880-887. PubMed ID: 34397207
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
Thaçi D; Unnebrink K; Sundaram M; Sood S; Yamaguchi Y
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):353-360. PubMed ID: 24846518
[TBL] [Abstract][Full Text] [Related]
34. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
Reich K; Conrad C; Kristensen LE; Smith SD; Puig L; Rich P; Sapin C; Holzkaemper T; Koppelhus U; Schuster C
J Dermatolog Treat; 2022 May; 33(3):1652-1660. PubMed ID: 33641593
[TBL] [Abstract][Full Text] [Related]
35. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails.
Kragballe K
Curr Probl Dermatol; 2009; 38():160-171. PubMed ID: 19710555
[TBL] [Abstract][Full Text] [Related]
36. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
Rompoti N; Katsimbri P; Kokkalis G; Boumpas D; Ikonomidis I; Theodoropoulos K; Rigopoulos D; Papadavid E
Dermatol Ther; 2019 Sep; 32(5):e13006. PubMed ID: 31228319
[TBL] [Abstract][Full Text] [Related]
37. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García EA; Herrera-Ceballos E
Dermatol Ther; 2020 May; 33(3):e13313. PubMed ID: 32181962
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
40. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
